PROGRAM CHAIRS
Balazs Halmos, MD, MS
Associate Director for Clinical Science
Director, Thoracic Oncology
Montefiore Einstein Comprehensive Cancer Center
Bronx, NY
Renato G. Martins, MD, MPH
Chief, Hematology, Oncology and Palliative Care
Professor of Medicine
Massey Comprehensive Cancer Center
Virginia Commonwealth University
Richmond, VA
PROGRAM OVERVIEW
This enduring activity will review mechanisms of action of immune checkpoint inhibitors (ICIs), the rationale for their use in combination with chemotherapy to treat metastatic, non-driver-mutated, non-small cell lung cancer (NSCLC), and common immune-related adverse events (irAEs) associated with these agents. This activity incorporates didactic presentation, illustrative animations, and case-based discussion. Throughout the program, expert faculty will guide you through relevant clinical trial data and current clinical practice guidelines, while sharing best practices for irAE management and optimal use of frontline ICI-based therapy.
TARGET AUDIENCE
This enduring activity is designed to meet the educational needs of global medical oncologists, oncology nurses, pharmacists, nurse practitioners, and other members of the multidisciplinary team in the community setting to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply clinical trials data from immunotherapy combination regimens in the first-line management of patients with advanced NSCLC
- Evaluate clinical practice guideline recommendations for first-line treatment of individuals with metastatic NSCLC without actionable mutations
- Review immunotherapy associated adverse events in patients with advanced NSCLC to enhance their prompt recognition and management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Balazs Halmos, MD | Discloses that he is a consultant for Astra Zeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squib, Genentech, Pfizer, Eli Lilly, Arcus Biosciences, and Merus. He has conducted research for Boehringer Ingelheim, Astra Zeneca, Merck, Bristol Meyers Squib, Advaxis, Amgen, AbbVie, Daiichi Sankyo, Pfizer, GlaxoSmithKline, BeiGene, Janssen, and Boehringer Ingelheim. |
| Renato G. Martins, MD | Dr. Martins discloses that he has been a consultant for Takeda Oncology. He has also received royalties from UpToDate. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, M, CCRC has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Kim L. Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, MS, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
